Source: Energias Market Research

Global Mycoplasma Testing Market to Witness a CAGR of 12.3% during 2018-2024

NEW YORK, July 27, 2018 (GLOBE NEWSWIRE) -- The global mycoplasma testing market was valued at USD 606.9 million in 2017, and is expected to reach USD 1358.2 million by 2024, at a CAGR of 12.3% during 2018-2024. The growth can be primarily attributed to the increasing incidence of mycoplasma contamination, and increasing research and development activities in the field of life sciences. In addition, increasing capital investment in the field of life sciences coupled with stringent regulatory norms to reduce contamination is also projected to drive the market during the forecast period.

Mycoplasma testing providing growth opportunities for the pharmaceutical and biotechnology industry

Cell culture has become an important tool for medical and biological research. In the biotechnology sector, they are increasingly used for drug screening and development, and large-scale manufacturing of biological compounds. Moreover, the application of cell in regenerative medicine, research laboratories, and biotechnological productions is growing extensively. Mycoplasma contamination affects the cell line growth and also affects the cell physiology and metabolism. The contamination may occur via contact with other formerly infected cultures. The mycoplasma contaminates the final biological products such as viral vaccines, immunologic modulators, cytokines, monoclonal antibodies, cell therapy products, resulting in the loss of the batches. Mycoplasma contamination is a significant problem in the biopharmaceutical industry, as it is a common cause of contamination in cell culture. There are various testing methods to confirm mycoplasma contamination such as staining, PCR (polymerase chain reaction), microbial culture techniques, ELISA (enzyme-linked immunosorbent assay), enzymatic methods, among others. All methods give effective results with both infected and non-infected cell lines. With Increasing research and development activities and growing demand for biopharmaceutical products, regulatory bodies such as FDA and EMA are expected to increasingly approve mycoplasma testing for biopharmaceutical products in coming years.

Mycoplasma Testing Market – Regional insight

Geographically, North America held the largest share of the market in 2017. The growth in the region is attributed to the increasing research and development activities in the biopharmaceutical industries and availability of the various types of kit and reagents. Moreover, continued research and development on new assays and kits, and growing demand from end-user industries such as pharmaceutical & biotechnology, cell banks, and contract service laboratories is further boosting the market growth in the region. Europe held the second largest share of the global mycoplasma testing market in 2017. Asia-Pacific is expected to grow at the highest CAGR during 2018-2024. The growth of the mycoplasma testing market in Asia-Pacific region is attributed to growing pharmaceutical and biotechnological industry and strong demand for mycoplasma testing from these sectors. Moreover, technological advancements in mycoplasma testing methods and increasing investment in R&D activities are further propelling the market growth in the region.

Browse full research report with TOC on “Global Mycoplasma Testing Market” Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024” at: https://www.energiasmarketresearch.com/global-mycoplasma-testing-market-report/

To purchase report: sales@energiasmarketresearch.com

Key findings from the report:

  • On the basis of product type, the kits & reagents segment held the major share of the market in 2017 owing to the growing research and development activities
  • On the basis of technology, the PCR (polymerase chain reaction) segment held the major share of the market. The growth in the segment is primarily due to PCR technology being highly sensitive and rapid method for detection of mycoplasma contamination. 
  • Based on application, the cell line testing segment held major share of the market in 2017
  • On the basis of end-user the pharmaceutical & biotechnology companies held the major share of the global market. This growth is attributed to the growing research and development activities for development of novel drugs, and strong demand for mycoplasma testing in biopharmaceutical products.
  • Geographically, North America  held the maximum share of the global market in 2017
  • Some of the key companies operating in the market include Roche Diagnostics, Lonza Group Ltd, Merck KGaA, PromoCell GmbH, InvivoGen, Charles River Laboratories, Inc., SGS SA, American Type Culture Collection, Bionique Testing Laboratories, Inc., Biological Industries Israel Beit Haemek Ltd, and among others

This report segments mycoplasma testing market based on product type, technology, application, end-user and region.

By Product Type

  • Instruments
  • Kits & Reagents
    • Elimination Kits & Reagent
    • Standards & Controls
    • PCR Assay
    • Stains
    • Nucleic Acid Detection
    • Other
  • Services

By Technology

  • ELISA (Enzyme-linked Immunosorbent Assay)
  • Microbial Culture Techniques
  • PCR (Polymerase Chain Reaction)
  • Indirect Assay
  • Enzymatic Methods
  • Direct Assay

By Application

  • Virus Testing
  • Cell Line Testing
  • End of Production Cells Testing
  • Other

By End-user

  • Academic Research Institutions and Organizations
  • Pharmaceutical & Biotechnology Companies
  • Cell Banks
  • Contract Service Laboratories
  • Government Agencies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

About Energias Market Research Pvt. Ltd.

Energias Market Research Pvt. Ltd. publishes high quality reports, in-depth market research studies, to help clients obtain investment level clarity on current business scenario, trends and segmentation for their future developments. We are committed to our client’s needs, by providing high quality custom reports solutions best fit for strategy development and implementation to high return of invest (RoI). We believe that exceptional problems need expertise to solve, and with the help of our industries expertise we are able to offer an in depth understanding of what’s crucial, what’s applicable, and what it takes to ensure accomplishment in any business or venture.

With a wide range of expertise from various industrial sectors and more than 50 industries that include energy, chemical and materials, information and communication technology, semiconductor and electronics industries, healthcare and daily consumer goods, etc., we strive to provide our clients with a one-stop solution for all research and consulting needs.


Mr. ManasNagi

Business Development Manager

For any queries email us: info@energiasmarketresearch.com

To purchase report: sales@energiasmarketresearch.com

Call us: +1-716-239-4915

Visit: https://www.energiasmarketresearch.com